United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Archer-Daniels-Midland Company

Boeing

Intel

Altria

Visa

Western Union

In the stock market, identifying promising investment opportunities is a pursuit that demands attention to detail and solid foresight. This article delves into the intricacies of seven stocks, each representing a unique sector with immense growth potential.

Million-Dollar Bets: 7 Stocks to Buy Before They Blast Off

Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE: PFE ) are being overlooked, but that's not bad news at all.

Pfizer's 2024 Comeback: A Dividend Gem in the Pharma Market

Pfizer's revenue is on the decline after reaching a record high back in 2022. However, the pharma giant is counting on new product approvals and business deals to spur a new phase of growth.

Is the Worst Over for Pfizer?

Pfizer Inc. stock has experienced a significant decline from its all-time high to the lowest price in over 10 years. Despite lower sales from its COVID-19 vaccines, Pfizer's other revenues grew 7% YoY in FY 2023. The decline in vaccine sales presents an opportunity for Pfizer to reinvest in research and development and develop new profitable products, which the market isn't appreciating.

Pfizer Is Down 54% From Highs, Now Yields 6.1%

Adtalem Global Education

Microsoft

To be blunt, buying a Wall Street recommended stock can be a mixed bag. While we trust experts in say the legal and medical fields, it's a different proposition in the equities space.

Listen to Wall Street and Buy These 3 Stocks Now

American Express

General Motors

Earnings season rolled on with corporate results issued at a fast clip. Overall, results continue to trend in a positive direction.

3 Standout Stocks That Crushed Q4 Earnings Estimates

Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript

Pfizer Inc. stock has plummeted due to collapsing revenues after the COVID-19 pandemic, but COVID-related sales are still meaningful. The stock is near a 10-year low but may be on the verge of a turnaround in 2024, with potential support from a 6% dividend yield. Pfizer's revenues have declined by 42% annually, but a return to growth is in store.

2024 Turnaround: Bottom Fishing With Pfizer

Pfizer reported better-than-expected revenue and adjusted earnings for the fourth quarter. This news spurred a jump for the pharma stock.

Why Pfizer Stock Was Jumping Today, but Then Gave Up Its Gains

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.

Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump

Pfizer Inc (NYSE:PFE)'s shares remained unmoved as its fourth-quarter result beat the Street by showing a surprise profit. For the three months ended December 31, the drugs giant reported earnings per share of 10 cents, against an expected loss of 22 cents, and revenue of $14.25 billion, slightly below the $14.42 billion anticipated.

Pfizer's earnings beat fails to mask longer-term challenges

Aside from a cavalcade of earnings, Case-Shiller came in lower month over month and JOLTS are out after the open.

GM Up on Q4 Beat & Raise; UPS, Pfizer Mixed

Pfizer Inc (NYSE:PFE) entered the earnings ring before the bell this morning, announcing fourth-quarter earnings of 10 cents per share, which is higher than analysts' anticipated losses of 22 cents.

Pfizer Reports Earnings; Stock Eyes 10th-Straight Monthly Loss

Pfizer Inc. (PFE) delivered a surprise profit in the fourth quarter despite a double-digit contraction in revenue. Pfizer shares were up 1.8% in early trading Tuesday following the release.

Pfizer Q4 Earnings Eke Out Unexpected Profit Despite Lower COVID Product Sales

Pfizer (PFE) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $1.14 per share a year ago.

Pfizer (PFE) Surpasses Q4 Earnings Estimates

Pfizer stock inched ahead Tuesday morning after unexpectedly reporting a fourth-quarter profit despite missing sales expectations.

Pfizer Reports Surprise Profit Despite Continued Covid Sales Downfall

Shares of Pfizer Inc. PFE, +0.04% gained 0.7% early Tuesday after the company beat analysts' earnings expectations and reaffirmed its full-year 2024 guidance issued in December.

Pfizer's stock rises as earnings beat expectations, company seeks ‘clean slate' in 2024

Pharmaceutical giant Pfizer on January 30th reported its financial results for Q4 and the full year of 2023. The company reported disappointing results, to say the least, including $58.5 billion in revenues for 2023 and $14.24 billion in revenues in Q4, down 42 percent and 41 percent from 2022 year-on-year.

Is there a doctor in the house? Pfizer reports critically low income and revenues in financial results

Pfizer reported a surprise quarterly profit on Tuesday, as COVID products demand was better than the company's expectations and research costs declined.

Pfizer posts surprise quarterly profit on resilient COVID products demand

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023. The fourth-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer's R&D pipeline can be found at www.pfizer.com. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We are encouraged by the stron.

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

B2Gold

Hasbro

Petroleo Brasileiro

Philip Morris

Rio Tinto plc Sponsored

Stellantis N.V. 

High-yield dividend stocks with potential for upside gains is essentially the Tony Robbins of market opportunities. Robbins gives you a big smile, a warm hug and invites into a total transformation package, turning all your visions, dreams and desires into reality.

7 High-Yield Dividend Stocks With High-Upside Potential

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

Merck

Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's first ever price negotiations.

Pharma industry to get US government price cut proposals by Thursday

Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.

Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?

Teladoc

Teladoc Health's strong position in an industry growing in prominence bodes well for its future. Pfizer is replacing its coronavirus products with a portfolio of newly approved medicines.

News for Pfizer Stock (PFE)